|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li X, Li X, Liao D, Wang X, Wu Z, Nie J,
Bai M, Fu X, Mei Q and Han W: Elevated microRNA-23a expression
enhances the chemoresistance of colorectal cancer cells with
microsatellite instability to 5-fluorouracil by directly targeting
ABCF1. Curr Protein Pept Sci. 16:301–309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Y, Samal E and Srivastava D: Serum
response factor regulates a muscle-specific microRNA that targets
Hand2 during cardiogenesis. Nature. 436:214–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duffy MJ: Carcinoembryonic antigen as a
marker for colorectal cancer: Is it clinically useful? Clin Chem.
47:624–630. 2001.PubMed/NCBI
|
|
5
|
Duffy MJ, van Dalen A, Haglund C, Hansson
L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C and Topolcan O:
Clinical utility of biochemical markers in colorectal cancer:
European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer.
39:718–727. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hammarstrom S: The carcinoembryonic
antigen (CEA) family: Structures, suggested functions and
expression in normal and malignant tissues. Semin Cancer Biol.
9:67–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hatfield SD, Shcherbata HR, Fischer KA,
Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is
regulated by the microRNA pathway. Nature. 435:974–978. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poy MN, Eliasson L, Krutzfeldt J, Kuwajima
S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P
and Stoffel M: A pancreatic islet-specific microRNA regulates
insulin secretion. Nature. 432:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Macedo LT, da Costa Lima AB and Sasse AD:
Addition of bevacizumab to first-line chemotherapy in advanced
colorectal cancer: A systematic review and meta-analysis, with
emphasis on chemotherapy subgroups. BMC Cancer. 12:892012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian S, Simon I, Moreno V, Roepman P,
Tabernero J, Snel M, van't Veer L, Salazar R, Bernards R and
Capella G: A combined oncogenic pathway signature of BRAF, KRAS and
PI3KCA mutation improves colorectal cancer classification and
cetuximab treatment prediction. Gut. 62:540–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang
YD, Yang Q and Xie DR: No survival benefit from adding cetuximab or
panitumumab to oxaliplatin-based chemotherapy in the first-line
treatment of metastatic colorectal cancer in KRAS wild type
patients: A meta-analysis. PLoS One. 7:e509252012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szafranska AE, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka
H, Boland CR and Goel A: Circulating microRNA-203 predicts
prognosis and metastasis in human colorectal cancer. Gut.
66:654–665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spizzo R, Nicoloso MS, Croce CM and Calin
GA: SnapShot: MicroRNAs in cancer. Cell. 137:586.e12009. View Article : Google Scholar
|
|
18
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Tsuchiya H, Zhang Y, Hartnett ME
and Wang L: MicroRNA-433 inhibits liver cancer cell migration by
repressing the protein expression and function of cAMP response
element-binding protein. J Biol Chem. 288:28893–28899. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Estep M, Armistead D, Hossain N, Elarainy
H, Goodman Z, Baranova A, Chandhoke V and Younossi ZM: Differential
expression of miRNAs in the visceral adipose tissue of patients
with non-alcoholic fatty liver disease. Aliment Pharmacol Ther.
32:487–497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
Identification of deregulated miRNAs and their targets in hepatitis
B virus-associated hepatocellular carcinoma. World J Gastroenterol.
18:5442–5453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo H, Zhang H, Zhang Z, Zhang X, Ning B,
Guo J, Nie N, Liu B and Wu X: Down-regulated miR-9 and miR-433 in
human gastric carcinoma. J Exp Clin Cancer Res. 28:822009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo LH, Li H, Wang F, Yu J and He JS: The
tumor suppressor roles of miR-433 and miR-127 in gastric cancer.
Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim EJ, Kang IH, Lee JW, Jang WG and Koh
JT: MiR-433 mediates ERR gamma-suppressed osteoblast
differentiation via direct targeting to Runx2 mRNA in C3H10T1/2
cells. Life Sci. 92:562–568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin X, Rice KL, Buzzai M, Hexner E, Costa
FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, et al:
miR-433 is aberrantly expressed in myeloproliferative neoplasms and
suppresses hematopoietic cell growth and differentiation. Leukemia.
27:344–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li R, Chung AC, Dong Y, Yang W, Zhong X
and Lan HY: The microRNA miR-433 promotes renal fibrosis by
amplifying the TGF-β/Smad3-Azin1 pathway. Kidney Int. 84:1129–1144.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: International Union Against Cancer (UICC) TNM Classification of
Malignant Tumors. 7th. Wiley-Blackwell; Oxford, UK: 2009
|
|
28
|
Tsai HL, Chu KS, Huang YH, Su YC, Wu JY,
Kuo CH, Chen CW and Wang JY: Predictive factors of early relapse in
UICC stage I–III colorectal cancer patients after curative
resection. J Surg Oncol. 100:736–743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kidner CA and Martienssen RA: Spatially
restricted microRNA directs leaf polarity through ARGONAUTE1.
Nature. 428:81–84. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Gao J, Gu J, Yuan J, Hua D and Shen
L: MicroRNA-215 inhibits relapse of colorectal cancer patients
following radical surgery. Med Oncol. 30:5492013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nair VS, Maeda LS and Ioannidis JP:
Clinical outcome prediction by microRNAs in human cancer: A
systematic review. J Natl Cancer Inst. 104:528–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hui A, How C, Ito E and Liu FF: Micro-RNAs
as diagnostic or prognostic markers in human epithelial
malignancies. BMC Cancer. 11:5002011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weiner-Gorzel K, Dempsey E, Milewska M,
McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A,
Sharpe D, et al: Overexpression of the microRNA miR-433 promotes
resistance to paclitaxel through the induction of cellular
senescence in ovarian cancer cells. Cancer Med. 4:745–758. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang XC, Ma Y, Meng PS, Han JL, Yu HY and
Bi LJ: miR-433 inhibits oral squamous cell carcinoma (OSCC) cell
growth and metastasis by targeting HDAC6. Oral Oncol. 51:674–682.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gotanda K, Hirota T, Matsumoto N and Ieiri
I: MicroRNA-433 negatively regulates the expression of thymidylate
synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa
cells. BMC Cancer. 13:3692013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Datar SA, Galloni M, de la Cruz A, Marti
M, Edgar BA and Frei C: Mammalian cyclin D1/Cdk4 complexes induce
cell growth in Drosophila. Cell Cycle. 5:647–652. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Harada K and Ogden GR: An overview of the
cell cycle arrest protein, p21(WAF1). Oral Oncol. 36:3–7. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yates CC, Shepard CR, Stolz DB and Wells
A: Co-culturing human prostate carcinoma cells with hepatocytes
leads to increased expression of E-cadherin. Br J Cancer.
96:1246–1252. 2007. View Article : Google Scholar : PubMed/NCBI
|
